Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Opus Genetics, Inc. (IRD)
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Independent Data Monitoring Committee (IDMC) issued a positive recommendation to continue as planned in the Company’s Phase 1/2 BEST1 clinical trial (BIRD-1), which is a multi-center, adaptive, open-label, dose-exploring study evaluating OPGx-BEST1 in participants with Best disease. The IDMC overseeing the trial completed its pre-specified safety review of the one-month data from the sentinel participant and recommended advancing enrollment and dosing of additional participants in the trial, without modification. “We are thrilled with this outcome from the first participant, whose encouraging safety results at one month enable us to proceed with dosing the next four partic
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Opus Genetics to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Opus Genetics (NASDAQ:IRD) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.MarketBeat
- Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.MarketBeat
IRD
Sec Filings
- 12/11/25 - Form SCHEDULE
- 12/11/25 - Form 4
- 11/12/25 - Form 10-Q
- IRD's page on the SEC website